HLVX logo

HilleVax (HLVX) Stock

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

29 April 2022

Indexes:

Not included

Description:

HilleVax (HLVX) is a biotechnology company focused on developing innovative vaccines. Their main goal is to create effective solutions for infectious diseases, improving public health. HilleVax aims to advance vaccine technology and provide safer, more effective options for patients worldwide.

Events Calendar

Earnings

Next earnings date:

Mar 20, 2025

Recent quarterly earnings:

Nov 07, 2024

Recent annual earnings:

Mar 20, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

12 Aug '24 HC Wainwright & Co.
Neutral
09 July '24 Stifel
Hold
09 July '24 Leerink Partners
Market Perform
09 July '24 HC Wainwright & Co.
Neutral
08 July '24 JP Morgan
Neutral
08 July '24 Guggenheim
Neutral
15 May '24 JP Morgan
Overweight
10 May '24 HC Wainwright & Co.
Buy
21 Mar '24 HC Wainwright & Co.
Buy
13 Dec '23 HC Wainwright & Co.
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Institutional Ownership

What Makes HilleVax (HLVX) a New Buy Stock
What Makes HilleVax (HLVX) a New Buy Stock
What Makes HilleVax (HLVX) a New Buy Stock
HLVX
zacks.com14 October 2024

HilleVax (HLVX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

HilleVax, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by HilleVax (HLVX)
HilleVax, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by HilleVax (HLVX)
HilleVax, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by HilleVax (HLVX)
HLVX
accesswire.com29 August 2024

NEW YORK, NY / ACCESSWIRE / August 29, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of HilleVax, Inc. ("HilleVax") (NASDAQ:HLVX) concerning possible violations of federal securities laws. On July 8, 2024, HilleVax was the subject of a Fierce Biotech article.

Levi & Korsinsky Investigates Possible Securities Fraud Violations by HilleVax, Inc. (HLVX)
Levi & Korsinsky Investigates Possible Securities Fraud Violations by HilleVax, Inc. (HLVX)
Levi & Korsinsky Investigates Possible Securities Fraud Violations by HilleVax, Inc. (HLVX)
HLVX
accesswire.com28 August 2024

NEW YORK, NY / ACCESSWIRE / August 28, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of HilleVax, Inc. ("HilleVax") (NASDAQ:HLVX) concerning possible violations of federal securities laws. On July 8, 2024, HilleVax was the subject of a Fierce Biotech article.

Investors who lost money on HilleVax, Inc. should contact Levi & Korsinsky about an ongoing investigation - HLVX
Investors who lost money on HilleVax, Inc. should contact Levi & Korsinsky about an ongoing investigation - HLVX
Investors who lost money on HilleVax, Inc. should contact Levi & Korsinsky about an ongoing investigation - HLVX
HLVX
accesswire.com27 August 2024

NEW YORK, NY / ACCESSWIRE / August 27, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of HilleVax, Inc. ("HilleVax") (NASDAQ:HLVX) concerning possible violations of federal securities laws. On July 8, 2024, HilleVax was the subject of a Fierce Biotech article.

HilleVax, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - HLVX
HilleVax, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - HLVX
HilleVax, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - HLVX
HLVX
accesswire.com26 August 2024

NEW YORK, NY / ACCESSWIRE / August 26, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of HilleVax, Inc. ("HilleVax") (NASDAQ:HLVX) concerning possible violations of federal securities laws. On July 8, 2024, HilleVax was the subject of a Fierce Biotech article.

ATTENTION HLVX SHAREHOLDERS: Investors who Lost Money on HilleVax, Inc. are Urged to Contact Levi & Korsinsky About an Ongoing Investigation
ATTENTION HLVX SHAREHOLDERS: Investors who Lost Money on HilleVax, Inc. are Urged to Contact Levi & Korsinsky About an Ongoing Investigation
ATTENTION HLVX SHAREHOLDERS: Investors who Lost Money on HilleVax, Inc. are Urged to Contact Levi & Korsinsky About an Ongoing Investigation
HLVX
accesswire.com23 August 2024

NEW YORK, NY / ACCESSWIRE / August 23, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of HilleVax, Inc. ("HilleVax") (NASDAQ:HLVX) concerning possible violations of federal securities laws. On July 8, 2024, HilleVax was the subject of a Fierce Biotech article.

ATTENTION HLVX SHAREHOLDERS: Investors who Lost Money on HilleVax, Inc. are Urged to Contact Levi & Korsinsky About an Ongoing Investigation
ATTENTION HLVX SHAREHOLDERS: Investors who Lost Money on HilleVax, Inc. are Urged to Contact Levi & Korsinsky About an Ongoing Investigation
ATTENTION HLVX SHAREHOLDERS: Investors who Lost Money on HilleVax, Inc. are Urged to Contact Levi & Korsinsky About an Ongoing Investigation
HLVX
accesswire.com22 August 2024

NEW YORK, NY / ACCESSWIRE / August 22, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of HilleVax, Inc. ("HilleVax") (NASDAQ:HLVX) concerning possible violations of federal securities laws. On July 8, 2024, HilleVax was the subject of a Fierce Biotech article.

HilleVax Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress
HilleVax Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress
HilleVax Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress
HLVX
globenewswire.com08 August 2024

$245.0 million of cash, cash equivalents and marketable securities as of June 30, 2024 The company is exploring the potential for continued development of its HIL-214 and HIL-216 norovirus vaccine candidates in adults BOSTON, Aug. 08, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial results for the quarter ended June 30, 2024 and highlighted recent progress. Recent Business Highlights In Q3 2024, HilleVax announced that the NEST-IN1 clinical study did not meet its primary or secondary efficacy endpoints and that the company would discontinue further development of HIL-214 in infants.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of HilleVax, Inc. - HLVX
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of HilleVax, Inc. - HLVX
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of HilleVax, Inc. - HLVX
HLVX
globenewswire.com03 August 2024

NEW YORK, Aug. 03, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  HilleVax, Inc. (“HilleVax” or the “Company”) (NASDAQ: HLVX).   Such investors are advised to contact Danielle Peyton at [email protected]  or 646-581-9980, ext. 7980.

Stakeholders Of Hillevax Inc Are Encouraged By The Schall Law Firm To Join The Alleged Securities Fraud Investigation
Stakeholders Of Hillevax Inc Are Encouraged By The Schall Law Firm To Join The Alleged Securities Fraud Investigation
Stakeholders Of Hillevax Inc Are Encouraged By The Schall Law Firm To Join The Alleged Securities Fraud Investigation
HLVX
accesswire.com26 July 2024

LOS ANGELES, CA / ACCESSWIRE / July 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of HilleVax, Inc. ("HilleVax" or "the Company") (NASDAQ:HLVX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

FAQ

  • What is the primary business of HilleVax?
  • What is the ticker symbol for HilleVax?
  • Does HilleVax pay dividends?
  • What sector is HilleVax in?
  • What industry is HilleVax in?
  • What country is HilleVax based in?
  • When did HilleVax go public?
  • Is HilleVax in the S&P 500?
  • Is HilleVax in the NASDAQ 100?
  • Is HilleVax in the Dow Jones?
  • When was HilleVax's last earnings report?
  • When does HilleVax report earnings?
  • Should I buy HilleVax stock now?

What is the primary business of HilleVax?

HilleVax (HLVX) is a biotechnology company focused on developing innovative vaccines. Their main goal is to create effective solutions for infectious diseases, improving public health. HilleVax aims to advance vaccine technology and provide safer, more effective options for patients worldwide.

What is the ticker symbol for HilleVax?

The ticker symbol for HilleVax is NASDAQ:HLVX

Does HilleVax pay dividends?

No, HilleVax does not pay dividends

What sector is HilleVax in?

HilleVax is in the Healthcare sector

What industry is HilleVax in?

HilleVax is in the Biotechnology industry

What country is HilleVax based in?

HilleVax is headquartered in United States

When did HilleVax go public?

HilleVax's initial public offering (IPO) was on 29 April 2022

Is HilleVax in the S&P 500?

No, HilleVax is not included in the S&P 500 index

Is HilleVax in the NASDAQ 100?

No, HilleVax is not included in the NASDAQ 100 index

Is HilleVax in the Dow Jones?

No, HilleVax is not included in the Dow Jones index

When was HilleVax's last earnings report?

HilleVax's most recent earnings report was on 7 November 2024

When does HilleVax report earnings?

The next expected earnings date for HilleVax is 20 March 2025

Should I buy HilleVax stock now?

As of today, analysts generally recommend a 'Hold' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions